| scholarly article | Q13442814 |
| P50 | author | Tom Huizinga | Q77086497 |
| Meriem Manaï | Q92451148 | ||
| P2093 | author name string | Dieuwke S Veldhuijzen | |
| Andrea W M Evers | |||
| Henriët van Middendorp | |||
| Joy A van der Pol | |||
| P2860 | cites work | Placebos without deception: a randomized controlled trial in irritable bowel syndrome | Q21091076 |
| The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis | Q28073981 | ||
| A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab | Q28282330 | ||
| Cytokines in the pathogenesis of rheumatoid arthritis | Q28303865 | ||
| The pathogenesis of rheumatoid arthritis | Q29614957 | ||
| Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score | Q33563148 | ||
| 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative | Q56506042 | ||
| Rheumatoid arthritis | Q56656479 | ||
| A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis | Q70405867 | ||
| The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin | Q70707294 | ||
| Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score | Q71843629 | ||
| Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis | Q73573994 | ||
| The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis | Q80330544 | ||
| Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial | Q80607339 | ||
| Psychometric qualities of the RAND 36-Item Health Survey 1.0: a multidimensional measure of general health status | Q81405407 | ||
| Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis | Q33567430 | ||
| Partial reinforcement, extinction, and placebo analgesia | Q33630729 | ||
| Conditioned pharmacotherapeutic effects: a preliminary study. | Q33772537 | ||
| The costs of rheumatoid arthritis: an international long-term view | Q33915358 | ||
| Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? | Q33986114 | ||
| Placebos: a review of the placebo response | Q33990782 | ||
| Effects of expectation on placebo-induced dopamine release in Parkinson disease | Q34129314 | ||
| Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort | Q34259444 | ||
| Conditioning of drug-induced physiological responses. | Q34280700 | ||
| The placebo effect: dissolving the expectancy versus conditioning debate. | Q34300478 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Expectations and associations that heal: Immunomodulatory placebo effects and its neurobiology. | Q34554013 | ||
| A comprehensive review of the placebo effect: recent advances and current thought | Q34634630 | ||
| Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis | Q34657863 | ||
| How placebo responses are formed: a learning perspective | Q35088475 | ||
| Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial | Q35552517 | ||
| EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). | Q35638360 | ||
| Benefit and risk of methotrexate treatment in rheumatoid arthritis | Q35955232 | ||
| Mechanisms of placebo and placebo-related effects across diseases and treatments | Q36897426 | ||
| Drug effects: agonistic and antagonistic processes | Q37636444 | ||
| Relieving pain using dose-extending placebos: a scoping review | Q37719487 | ||
| Utilizing placebo mechanisms for dose reduction in pharmacotherapy | Q37979359 | ||
| Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature | Q38011225 | ||
| Evolution of treatment for rheumatoid arthritis | Q38065767 | ||
| Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs | Q38471394 | ||
| Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice | Q38540866 | ||
| One year in review: the pathogenesis of rheumatoid arthritis | Q38552699 | ||
| Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices | Q40199606 | ||
| Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. | Q40550160 | ||
| The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials | Q40914450 | ||
| Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. | Q41922543 | ||
| Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group | Q41924053 | ||
| A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study | Q41925567 | ||
| Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies | Q41941018 | ||
| Children's and parents' perspectives on open-label use of placebos in the treatment of ADHD. | Q42641275 | ||
| COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention | Q43882911 | ||
| Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight–week randomized, double-blind trial | Q43983874 | ||
| Inducing placebo respiratory depressant responses in humans via opioid receptors | Q44351413 | ||
| Conditioning of cyclophosphamide-induced leukopenia in humans. | Q52203339 | ||
| Conditioned responses in pharmacotherapy research. | Q52225453 | ||
| The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses. | Q53336804 | ||
| P433 | issue | 1 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| study protocol | Q111908491 | ||
| P304 | page(s) | 15 | |
| P577 | publication date | 2020-01-06 | |
| P1433 | published in | Trials | Q7840023 |
| P1476 | title | Pharmacological conditioning in the treatment of recent-onset rheumatoid arthritis: a randomized controlled trial study protocol | |
| P478 | volume | 21 |
| Q89599681 | Pharmacological conditioning for juvenile idiopathic arthritis: a potential solution to reduce methotrexate intolerance | cites work | P2860 |
Search more.